English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Wang Liang

Title：Chief Physician
Position：Division Chief 
Personal Profile：Chief Physician, Professor, Ph.D. Supervisor, currently the Director of Hematology Department of Peking Tongren Hospital.He graduated from Peking Union Medical College in 2010, majoring in Clinical Medicine in the eight-year system, and obtained the Doctor of Medicine degree. He has been engaged in the diagnosis and treatment of hematologic tumors (lymphoma, multiple myeloma, etc.) for more than 10 years, and has rich clinical experience and high academic attainments in the diagnosis and treatment of various types of lymphomas and myelomas, and specializes in targeted immunotherapy, chemotherapy, CAR-T cell therapy, hematopoietic stem cell transplantation, and leading the development of multidisciplinary diagnosis and treatment (MDT). His main research interests are targeted immunotherapy and drug resistance mechanism exploration of lymphoma, and he has presided over a number of National Natural Science Foundation of China. He has published more than 40 professional papers, including more than 30 SCI-indexed papers, which have been published in Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer Therapy Reviews, and other journals and journals. He has published in Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer, British Journal of Cancer, Annals of Hematology, and Leukemia & Lymphoma. He is the co-editor of Standard Leukemia Diagnosis and Treatment, Standard Multiple Myeloma Diagnosis and Treatment, and Medical Oncology. He was awarded the “Respect for Life-2017 Glory to Healers-Youth Innovation Award”, “Tongren Elite” award in 2020, “Tongren Hospital Outstanding Young Talent” award in 2020, and the first “Tongren Hospital Outstanding Young Talent” award in 2020. Tongren Hospital Outstanding Young Talent” in 2020, ‘35 Young Oncologists Under 35 with the Most Potential in China’. Academic Affiliations: Young Member of the Hematology Branch of the Chinese Medical Association; Standing Member of the Lymphoma Immunotherapy Committee of the Beijing Cancer Prevention and Control Society; Standing Member of the Myeloma Committee of the China Medical Education Association; Expert of the National Natural Science Foundation of China. He is an associate editor of Aging Pathobiology and Therapeutics, an editorial board member of Chinese Journal of Cancer Prevention and Control, a young editorial board member of Concord Medical Journal, and a reviewer of Journal of Hematology & Oncology and Cancer Biology & Medicine.

Wang Liang